Shareholder Alert: The Ademi Firm Continues to Investigate the Blueprint Medicines Corporation Transaction
Blueprint Medicines(US:BPMC) Businesswireยท2025-09-15 05:10Core Insights - The Ademi Firm is investigating Blueprint (Nasdaq: BPMC) regarding its transaction with Sanofi, focusing on potential insider benefits and conflicts of interest [1] Group 1 - Blueprint insiders received substantial benefits as part of change of control arrangements [1] - Certain insiders may have had conflicts of interest related to the transaction [1]